GlassScriptPhysician profile
Ehab M Kodsi
NPI 1063594752
$11,114.06
in general payments reported to CMS, 2019-2025
46 companies · $31.13 in 2025
The $31.13 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $1,467 · 2021: $2,096 · 2022: $2,523 · 2023: $2,516 · 2024: $1,258 · 2025: $31.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,801 · Education: $3.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,801.14 |
| Education | $3.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,274.72 | 2021-2024 | |
| Allergan, INC. | $852.90 | 2019-2022 | |
| Horizon Therapeutics Plc | $687.12 | 2019-2023 | Tepezza, Krystexxa |
| Collegium Pharmaceutical, INC. | $518.77 | 2019-2024 | Xtampza, Belbuca |
| Pfizer INC. | $471.60 | 2019-2024 | |
| Amgen INC. | $447.92 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $446.46 | 2019-2024 | Ztlido |
| Merz Pharmaceuticals, LLC | $424.50 | 2021-2023 | Xeomin |
| Arbor Pharmaceuticals, INC. | $412.77 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $372.81 | 2019-2023 | Oxtellar Xr, Trokendi Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $345.26 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $305.38 | 2019-2023 | Ajovy |
| Biohaven Pharmaceuticals, INC. | $288.66 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $276.12 | 2022-2023 | Seglentis |
| Lilly USA, LLC | $215.52 | 2019-2024 | Emgality, Reyvow |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $211.55 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $202.03 | 2022-2024 | Dysport |
| Depuy Synthes Sales INC. | $192.37 | 2019-2024 | Orthovisc, Monovisc |
| Novo Nordisk INC | $169.27 | 2021-2024 | Wegovy |
| Fidia Pharma USA INC. | $169.03 | 2019-2024 | Triluron, Hymovis, Hyalgan |
| Lundbeck LLC | $162.63 | 2022-2025 | Vyepti |
| Azurity Pharmaceuticals, INC. | $155.79 | 2023 | Horizant |
| Merz North America, INC. | $144.91 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $141.72 | 2023 | Trudhesa |
| Mdd US Operations, LLC | $135.02 | 2019-2021 | |
| Pacira Therapeutics, INC. | $126.85 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $107.95 | 2023-2024 | Zilretta, Iovera |
| Novartis Pharmaceuticals Corporation | $107.60 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $90.09 | 2022-2023 | Euflexxa |
| International Rehabilitative Sciences, INC | $87.54 | 2024 | Rs 4i Plus Sequential Stimulator |
| Bioventus LLC | $84.99 | 2022-2024 | Gelsyn-3, Durolane |
| Avanir Pharmaceuticals, INC. | $66.91 | 2020-2021 | |
| Metacel Pharmaceuticals LLC | $58.05 | 2022-2024 | Ozobax |
| Medtronic, INC. | $48.89 | 2021-2022 | |
| Eisai INC. | $47.97 | 2021 | |
| Averitas Pharma INC. | $42.61 | 2024 | Qutenza |
| Biodelivery Sciences International, INC. | $42.53 | 2019-2021 | |
| Daiichi Sankyo INC. | $34.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.38 | 2021 | |
| Avanos Medical | $27.62 | 2024 | Trivisc Sodium Hyaluronate |
| Biogen, INC. | $17.12 | 2019 | |
| Medline Industries LP | $16.39 | 2023 | |
| Djo, LLC | $14.83 | 2022 | |
| Medtronic USA, INC. | $14.46 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $13.42 | 2024 | |
| Athena Bioscience, LLC | $10.22 | 2023 | Qdolo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehab Kodsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.